WGS — GeneDx Holdings Corp. Stock Price, Chart & AI Report

Negative May 27, 2026 • 23:47 UTC GlobeNewswire Inc. • Hagens Berman

GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative – Hagens Berman

GeneDx Holdings stock plummeted 49% on May 5, 2025, after the company reported a massive Q1 2026 earnings miss, a tenfold increase in net loss, and significantly reduced full-year guidance. The company's average reimbursement rate fell short of expectations due to an adverse shift in product mix toward lower-margin genome tests. Hagens Berman has opened an investigation into potential securities law violations regarding whether management misled investors about product mix changes and growth projections.

WGS WGSWW securities fraud earnings miss guidance reduction product mix shift shareholder investigation clinical diagnostics

Sentiment note

Company experienced a 49% stock price decline following a massive earnings miss, tenfold increase in net loss, drastic guidance reduction, and $900M market cap loss in a single day. Management allegedly misled investors about product mix changes and growth expectations, triggering a securities investigation.

Positive May 23, 2026 • 20:17 UTC The Motley Fool • Jonathan Ponciano

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

Prosight Management invested $42.72 million in GeneDx Holdings by purchasing 468,463 shares, bringing its stake to 5.51% of AUM. Despite GeneDx stock declining 30% over the past year, the investment reflects confidence in the company's genomic testing growth, with Q1 2026 showing 34% volume growth and 27% revenue growth in exome/genome testing, though full-year revenue guidance was lowered.

WGS WGSWW genomics healthcare investment precision medicine AI-driven diagnostics clinical data analysis institutional investment

Sentiment note

Strong operational metrics with 34% testing volume growth, 27% exome/genome revenue growth, and management guidance for 30%+ volume growth this year. Institutional investor confidence demonstrated by Prosight's $43M investment despite stock price decline. The company's AI-powered platform and expanding genomic database position it well for precision medicine adoption, though profitability remains a concern.

Neutral May 21, 2026 • 14:23 UTC The Motley Fool • Robert Izquierdo

Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?

GeneDx board member Keith Meister purchased 351,273 shares for $13.8 million in May 2026, signaling bullish sentiment on the stock. The purchase came after shares plummeted 40.68% over one year to a 52-week low, resulting in an attractive 3x price-to-sales ratio. While the company shows 17% revenue growth, it reported a massive $63.3 million Q1 net loss, partly due to a $31.3 million impairment write-down from the Fabric Genomics acquisition. The investment case hinges on whether GeneDx can achieve long-term profitability.

WGS WGSWW insider buying GeneDx healthcare AI genomic data valuation profitability concerns

Sentiment note

While insider buying by a major shareholder suggests confidence in valuation, the company faces significant headwinds including a 40.68% one-year decline, massive net losses ($63.3M in Q1), and an impairment write-down. The positive sentiment from the insider purchase is offset by operational challenges and the company's path to profitability remaining uncertain. The stock is attractively valued but represents a speculative turnaround play rather than a clear buy.

Negative May 19, 2026 • 22:22 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm

Law firm Bragar Eagel & Squire is investigating GeneDx Holdings Corp. for potential securities law violations following the company's May 4, 2026 earnings report that revealed a $57.5 million operational loss, $65 million revenue guidance cut, and a $31.3 million goodwill write-down. GeneDx shares plummeted 50% from $67.93 to $34.51 on the news, citing lower-than-expected reimbursement rates and weak performance from its Fabric Genomics unit.

WGS WGSWW securities investigation earnings miss revenue guidance cut goodwill impairment stock decline shareholder losses

Sentiment note

Company reported significant operational losses ($57.5M), substantial revenue guidance reduction ($65M), major goodwill write-down ($31.3M), and triggered a 50% stock price decline. Additionally, the company faces a securities investigation for potential violations, indicating serious business and legal challenges.

Negative May 18, 2026 • 23:00 UTC GlobeNewswire Inc. • Kirby Mcinerney Llp

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

GeneDx Holdings Corp. (NASDAQ: WGS) faces a securities investigation following disappointing Q1 2026 results, including a $57.5 million operating loss, $65 million revenue guidance cut, and a $31.3 million goodwill write-down for its Fabric Genomics unit. The stock plummeted 50% from $67.93 to $34.51 on May 5, 2026, following the May 4 earnings announcement.

WGS WGSWW securities investigation earnings miss revenue guidance cut goodwill write-down stock decline reimbursement rate

Sentiment note

Company reported significant losses, substantial revenue guidance reduction, major asset write-downs, and a 50% stock price decline. The securities investigation suggests potential disclosure violations regarding the severity of business challenges.

Negative May 13, 2026 • 23:00 UTC GlobeNewswire Inc. • Kirby Mcinerney Llp

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

GeneDx Holdings Corp. (NASDAQ: WGS) faces a securities investigation following disappointing Q1 2026 results, including a $57.5 million operating loss, $65 million revenue guidance cut, and a $31.3 million goodwill write-down for its Fabric Genomics unit. The stock plummeted 50% from $67.93 to $34.51 on May 5, 2026, following the May 4 earnings announcement.

WGS WGSWW securities investigation earnings miss revenue guidance cut goodwill write-down stock decline reimbursement rate

Sentiment note

Company reported significant losses, substantial revenue guidance reduction, major asset write-downs, and a 50% stock price decline. Additionally, a securities investigation has been initiated regarding potential violations of federal securities laws, indicating serious concerns about management's disclosure practices and business performance.

Negative May 9, 2026 • 13:50 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating GeneDx Holdings Corp. following a 50% stock price decline on May 5, 2026. The company reported Q1 2026 losses of $0.28 per share, a $57.5 million operational loss, and slashed 2026 revenue guidance by $65 million due to lower-than-expected reimbursement rates and weak performance from its Fabric Genomics unit, which incurred a $31.3 million goodwill write-down.

WGS WGSWW securities investigation stock price decline earnings miss revenue guidance cut goodwill write-down class action lawsuit

Sentiment note

Company reported significant losses, slashed revenue guidance by $65 million, took a $31.3 million goodwill write-down, and experienced a 50% stock price decline. Additionally, a securities investigation has been initiated by a law firm on behalf of stockholders, indicating potential violations of federal securities laws.

Negative May 6, 2026 • 22:57 UTC GlobeNewswire Inc. • Block & Leviton Llp

BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses

ADMA Biologics shares fell over 24% after withdrawing long-term financial guidance due to market competitive dynamics and allegations of inflated growth through channel stuffing. Primoris Services stock declined over 45%, and GeneDX shares plummeted over 45% on May 5th. Block & Leviton is investigating all three companies for potential securities law violations and encouraging affected investors to seek recovery.

ADMA PRIM WGS WGSWW securities fraud stock decline class action investigation channel stuffing

Sentiment note

Shares plummeted over 45% on May 5th; under investigation for potential securities law violations

Negative May 6, 2026 • 14:12 UTC The Motley Fool • Rick Munarriz

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday as all three stocks experienced significant declines. Shopify fell 16% after disappointing guidance despite strong quarterly results. GeneDX plummeted 49% following weak earnings and a major downward revision of full-year revenue guidance. Intellia Therapeutics had a modest 4% decline and remains supported by positive clinical trial data.

SHOP NTLA WGS WGSWW Cathie Wood Ark Invest bargain hunting stock decline

Sentiment note

Stock plummeted 49% after disappointing Q1 results with only 17% revenue growth versus expected ~30%. Company significantly cut full-year 2026 revenue guidance from $540-555M to $475-490M (midpoint down $65M). Shortfalls in reimbursement rates and bottom-line performance suggest deteriorating near-term outlook.

Neutral Apr 8, 2026 • 15:32 UTC The Motley Fool • Rick Munarriz

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest purchased shares of three underperforming growth stocks on Tuesday: Robinhood Markets (down 38% YTD), GeneDX (down 49% YTD), and Tesla (down 23% YTD). Wood added to existing positions despite recent challenges including Robinhood's slowing revenue growth, GeneDX's sharp decline from December peaks, and Tesla's first year of declining revenue in 2025.

HOOD WGS WGSWW TSLA bargain hunting growth stocks Cathie Wood Ark Invest

Sentiment note

Worst performer on the list (down 49% YTD) with sharp 60% decline from December peak, but fundamentals remain solid with 40% revenue growth last year and projected 20%+ growth for next four years. Profitable on adjusted basis since 2024, suggesting recovery potential despite recent correction.

Positive Mar 10, 2026 • 15:15 UTC The Motley Fool • Rick Munarriz

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in three stocks on Monday: Joby Aviation (eVTOL aircraft), GeneDx Holdings (genetic testing), and DraftKings (sports wagering). All three have declined significantly from their peaks but show promising fundamentals and growth potential. Joby announced a White House partnership enabling service in 10 states later this year.

JOBY JOBY.WS WGS WGSWW Cathie Wood Ark Invest bargain hunting growth investing

Sentiment note

Company shows strong fundamentals with 40% revenue growth to $427.5M and rapidly narrowing losses (down from $433M to $21M deficit). Analysts expect profitability by next year. 45% pullback from peak presents buying opportunity.

Positive Dec 9, 2025 • 14:03 UTC The Motley Fool • Sarah Sidlow

GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

GeneDX CEO Katherine Stueland sold 2,158 shares on October 29, 2025, primarily to cover tax obligations after converting restricted stock units. The transaction was part of routine accounting and does not indicate a loss of confidence in the company.

WGS WGSWW genetic testing AI healthcare technology insider trading stock sale

Sentiment note

The company has seen an 84% stock price increase in one year, is leveraging AI in genomic testing, and operates in a growing healthcare technology market with strong future potential